跳至主要内容
临床试验/CTRI/2022/06/043510
CTRI/2022/06/043510尚未招募未知

An Open-Label, Single-Arm Clinical Study to evaluate the Safety and Tolerability of Purim Tablet in Healthy Adultsâ??

Himalaya Wellness Company0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
尚未招募

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Healthy adult subjects of either sex aged between >=18 to <=50 years.
  • 2. Subjects willing to sign informed consent and follow the study procedure.
  • 3. Has not participated in a similar investigation in the past four weeks.
  • 4. Subjects willing to refrain taking any other nutritional supplement during the study period

排除标准

  • 1. Subjects with clinically significant serious cardiovascular, cerebrovascular, respiratory, liver, renal disease, congenital or any other disorder.
  • 2. Subjects with any abnormal lab values detected at screening shall be excluded.
  • 3. A known history or present condition of allergic response to pharmaceutical products its components or ingredients in the investigational products (IP).
  • 4. Pre-existing systemic disease necessitating long-term medications.
  • 5. Genetic and endocrinal disorders.
  • 6. Subjects who refused to sign informed consent.
  • 7. Pregnant and lactating women.

研究者

相似试验

Evaluation of Safety and Tolerability of Purim... | 临床试验